Year: 2020

SP Group generated EBITDA of DKK 258.6 million in the 9M 2020 reporting period, a 9.4% improvement from DKK 236.3 million in 9M 2019. Revenue improved by 7.5% year on year to DKK 1,622.4 million and profit before tax was up 0.3% to DKK 138.7 million. The FY 2020 guidance released in Announcement no. 34/2020 is upgraded and ranges narrowed. We now expect FY 2020 revenue in the DKK 2.1–2.2 billion range and an EBITDA margin of 15.5-16.0%.See also attached stock announcement no. 46/2020.AttachmentsMeddelelse nr. 46 – Q3 – ENG – 12 11 20Meddelelse nr. 46 – Q3 – DA – 12 11 20

SP Group realiserede i de første 3 kvartaler 2020 et EBITDA på DKK 258,6 mio. mod DKK 236,3 mio. i samme periode sidste år svarende til en stigning på 9,4 %. Omsætningen målt i forhold til samme periode sidste år steg 7,5 % til DKK 1.622,4 mio., og resultatet før skat steg 0,3 % til DKK 138,7 mio. Forventningerne til 2020 som offentliggjort i selskabsmeddelelse nr. 34/2020 præciseres og opjusteres. Der forventes nu en omsætning i 2020 i niveauet DKK 2,1 – 2,2 mia. med en EBITDA margin på 15,5 – 16,0 %.  Se vedhæftede selskabsmeddelelse nr. 46/2020.Vedhæftet filMeddelelse nr. 46 – Q3 – DA – 12 11 20

– On Track to Complete GMP Batch Runs in Mid-2021 to Confirm Comparability Between TARA-002 and OK-432 –– Expect to Initiate Phase 1 Trial for TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer in 2021 –– Requested Meeting with FDA to Discuss Path Forward for TARA-002 in Lymphatic Malformations –– Strong Cash Position of $166M as of September 30, 2020 –NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the third quarter ended September 30, 2020.“The third quarter marked a highly productive time for the Company, notably with the Food and Drug Administration’s (FDA) confirmation...

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2020 and provides a corporate update.“The third quarter saw continued advancement and validation of our clinical development programs, with a focus on our oncology pipeline of replicating arenavirus-based therapeutic candidates,” commented Joern Aldag, Chief Executive Officer of HOOKIPA. “We continue to gain momentum as we expanded our ongoing Phase 1/2 HPV trial to explore HB-202/HB-201 as an alternating vector therapy with the first patient dosed with HB-202. We are also pleased that preclinical immunogenicity data from HB-201, our...

– Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors –– Clinical Collaborations Signed with Janssen, Pfizer and Precision Biosciences to Evaluate Nirogacestat in Combination with BCMA-Directed Therapies Across Modalities for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma –– Entered into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma –– Completed an Asset Purchase and Exclusive License Agreement of Global Rights to FAAH Inhibitor PF-04457845 to Jazz Pharmaceuticals, Receiving $35 Million Upfront Payment and Potential Future Milestone Payments of Up to $375 Million –– Raised $269.5 Million in Net Proceeds Through...

London, UK, Nov. 12, 2020 (GLOBE NEWSWIRE) —· Third quarter and post-period highlights: 

Shenzhen, China, Nov. 12, 2020 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (Nasdaq: XNET), a leading innovator in shared cloud computing and blockchain technology in China, today announced its unaudited financial results for the third quarter ended September 30, 2020.Third Quarter 2020 Financial Highlights:Total revenues were US$43.7 million, representing a decrease of 1.4% from the previous quarter.Cloud computing and other internet value-added services (“Cloud computing and other IVAS”) revenues were US$21.2 million, representing an increase of 1.1% from the previous quarter.Subscription revenues were US$19.6 million, representing a decrease of 5.5% on a sequential basis.Online advertising revenues (consisting primarily of revenues from mobile advertising) were approximately US$3.0 million, representing an increase...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE “CODE”) AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT ANY FIRM OFFER WILL BE MADE NOR AS TO THE TERMS ON WHICH ANY FIRM OFFER MIGHT BE MADE.THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) notes the recent market speculation and movement in the share price of Elementis and confirms that it made an approach on 5 November...

The negative impact of COVID-19 on scan volume at all MRI imaging centers managed by FONAR’s subsidiary, Health Management Company of America (HMCA), continued throughout the first quarter of fiscal 2021. However, collective MRI scan volume increased by 50% to 41,566 for the 3-month period ended September 30, 2020, as compared to 27,757 scans for the previous 3-month period ended June 30, 2020. To date, the most severe effects of the pandemic on MRI scan volume occurred during the 3-month ended June 30, 2020.Total MRI scan volume at the HMCA-managed sites decreased 13% to 41,566 scans for the three month period ending September 30, 2020 as compared to 47,027 scans one year earlier. The impact from COVID-19 on MRI scan volume for the future cannot be forecasted at this time.Cash and cash equivalents and short term investments increased...